PathXL Diagnostics

PathXL Diagnostics specializes in digital pathology solutions, enhancing diagnostic workflows through innovative technology and comprehensive laboratory systems designed to streamline clinical processes and improve patient care. Founded in 2005 and headquartered in Belfast, UK, PathXL Diagnostics operates in the digital pathology space, focusing on innovative diagnostic solutions. The company was acquired by Royal Philips in June 2016, though financial terms were not disclosed. PathXL has participated in 8 deals, with its most recent funding round occurring in June 2016, raising GBP 2.

28 mn from Crescent Capital. This funding represents the total amount raised by the company, amounting to GBP 2. 28 mn. PathXL Diagnostics offers a range of digital pathology solutions that enhance laboratory efficiency.

Their core products include the ULTRA Laboratory Information System (LIS) and the Cirdan Tutor, a digital education platform for pathologists. Additionally, they provide imaging solutions such as Solas OR and Core Lite systems, which cater to specific laboratory needs. These offerings serve a wide array of clients including national laboratories, hospitals, and pathology labs worldwide, addressing the growing demand for automated laboratory solutions. PathXL Diagnostics recorded revenues of GBP 0 in the most recent year of 2021.

The company reported an EBITDA of GBP 0 in 2023. Their revenue model is primarily based on B2B partnerships, driven by sales of core products such as the ULTRA LIS and Solas OR systems, alongside ongoing support and software updates for clients. Going forward, PathXL Diagnostics aims to expand its product line with new offerings that are currently under development. The company intends to penetrate additional geographic markets, specifically targeting regions in Europe and North America by 2025.

The funding raised in June 2016 will support these initiatives, enabling the company to enhance its product development and market outreach strategies.